- Home
- ACLX vs RARE Comparison
ACLX vs RARE Comparison
Compare ACLX & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLX
- RARE
- Stock Information
- Founded
- ACLX 2015
- RARE 2010
- Country
- ACLX United States
- RARE United States
- Employees
- ACLX 163
- RARE N/A
- Industry
- ACLX Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ACLX Health Care
- RARE Health Care
- Exchange
- ACLX Nasdaq
- RARE Nasdaq
- Market Cap
- ACLX 3.5B
- RARE 3.3B
- IPO Year
- ACLX 2022
- RARE 2014
- Fundamental
- Price
- ACLX $63.00
- RARE $37.14
- Analyst Decision
- ACLX Strong Buy
- RARE Strong Buy
- Analyst Count
- ACLX 14
- RARE 15
- Target Price
- ACLX $111.42
- RARE $90.53
- AVG Volume (30 Days)
- ACLX 631.2K
- RARE 1.2M
- Earning Date
- ACLX 08-07-2025
- RARE 07-31-2025
- Dividend Yield
- ACLX N/A
- RARE N/A
- EPS Growth
- ACLX N/A
- RARE N/A
- EPS
- ACLX N/A
- RARE N/A
- Revenue
- ACLX $76,809,000.00
- RARE $590,689,000.00
- Revenue This Year
- ACLX N/A
- RARE $18.94
- Revenue Next Year
- ACLX $112.68
- RARE $28.93
- P/E Ratio
- ACLX N/A
- RARE N/A
- Revenue Growth
- ACLX N/A
- RARE 33.46
- 52 Week Low
- ACLX $47.86
- RARE $29.59
- 52 Week High
- ACLX $107.37
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ACLX 47.45
- RARE 52.29
- Support Level
- ACLX $64.77
- RARE $36.01
- Resistance Level
- ACLX $66.73
- RARE $40.19
- Average True Range (ATR)
- ACLX 2.89
- RARE 1.47
- MACD
- ACLX -0.35
- RARE 0.06
- Stochastic Oscillator
- ACLX 25.18
- RARE 49.92
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.